1. bookAHEAD OF PRINT
Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
access type Accesso libero

Intravenous Treatment Adherence of Patients with Chronic Inflammatory Rheumatic Diseases During the COVID-19 Pandemic: Experience of a Single Center

Dettagli della rivista
License
Formato
Rivista
eISSN
2501-062X
Prima pubblicazione
30 Mar 2015
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Abstract

Introduction: Patients with chronic inflammatory rheumatic diseases (CIRD) who receive intravenous therapy requiring hospitalization are likely to be more affected than those with receiving oral therapy during COVID-19 pandemic. We aimed to investigate the effect of the COVID-19 pandemic on adherence to treatment in patients with CIRD receiving intravenous treatments.

Methods: We evaluated patients with CIRD who were treated with intravenous immunosuppressive therapy such as rituximab (RTX), cyclophosphamide (CTX), infliximab (IFX), tocilizumab (TCZ) and abatacept (ABA) in our inpatient rheumatology clinic. The patients’ medical treatment compliance and clinical follow-up were evaluated. Treatment discontinuation was decided according to postponement of at least one dose and discontinuation of CIRD treatments. Demographics and clinical characteristics were compared between treatment-incompliant (TI) and treatment-compliant (TC) groups.

Results: A total of 181 CIRD patients were enrolled. Rheumatoid arthritis was the most common disease requiring intravenous immunosuppressive treatment followed by axial spondyloarthritis and Behçet’s disease. Joint involvement was the most common followed by lung and kidney involvements. Rituximab was the most widely used intravenous immunosuppressive treatment for the CIRD. 34% patients have postponed at least one dose of their intravenous CIRD treatment and 25% discontinued. Fear of COVID-19 and SARS-CoV-2 positivity were the most common reasons. The TI group had a longer disease duration and a higher frequency of inflammatory arthritis than the TC group (p=0.013 and p=0.044, respectively).

Conclusions: Fear of COVID-19 and SARS-CoV-2 positivity seemed to be the major reasons for discontinuing/postponing intravenous treatments in CIRD patients. Patients with long disease duration and less systemic involvement may be more prone to discontinuing their treatments.

Keywords

1. KİM Y, AHN E, LEE S, LİM DH, KİM A, LEE SG., et al. Changing Patterns of Medical Visits and Factors Associated with No-show in Patients with Rheumatoid Arthritis during COVID-19 Pandemic. J Korean Med Sci. 2020;35(48):e423.10.3346/jkms.2020.35.e423 Search in Google Scholar

2. HASÖKSÜZ M, KİLİÇ S, SARAÇ F. Coronaviruses and sars-cov-2. Turkish journal of medical sciences. 2020;50(SI-1):549-56.10.3906/sag-2004-127 Search in Google Scholar

3. POPE JE. What does the COVID-19 pandemic mean for rheumatology patients? Current treatment options in rheumatology. 2020;6(2):71-4.10.1007/s40674-020-00145-y Search in Google Scholar

4. RİCHEZ C, LAZARO E, LEMOİNE M, TRUCHETET M-E, SCHAEVERBEKE T. Implications of COVID-19 for the management of patients with inflammatory rheumatic diseases. Joint Bone Spine. 2020;87(3):187.10.1016/j.jbspin.2020.03.010 Search in Google Scholar

5. SAADOUN D, VİEİRA M, VAUTİER M, BARALİAKOS X, ANDREİCA I, DA SİLVA JA., et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. The Lancet Rheumatology. 2021.10.1016/S2665-9913(21)00112-0 Search in Google Scholar

6. PABLOS JL, GALİNDO M, CARMONA L, LLEDÓ A, M RETUERTO, BLANCO R., et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis, 2020. 79(12): p. 1544-1549.10.1136/annrheumdis-2020-218296743018532796045 Search in Google Scholar

7. MONTERO F, MARTÍNEZ-BARRİO J, SERRANO-BENAVENTE B, GONZÁLEZ T, RİVERA J, MOLİNA COLLADA J., et al. Coronavirusdisease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int, 2020. 40(10): p. 1593-1598.10.1007/s00296-020-04676-4742525432794113 Search in Google Scholar

8. SANTOS CS, FÉRNANDEZ XC, MORALES CM, ÁLVAREZ ED, CASTRO CÁ, ROBLES AL., et al. Biologicalagentsforrheumaticdiseases in theoutbreak of COVID-19: friendorfoe? RMD Open, 2021. 7(1).10.1136/rmdopen-2020-001439781340733455920 Search in Google Scholar

9. Turkish Rheumatology Association Coronavirus (Covid-19) Outbreak Recommendations (2020) March 27th Title. Search in Google Scholar

10. GABRİEL SE, MİCHAUD K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis research & therapy. 2009;11(3):229.10.1186/ar2669271409919519924 Search in Google Scholar

11. SFRİSO P, GHİRARDELLO A, BOTSİOS C, TONON M, ZEN M, BASSİ N., et al. Infections and autoimmunity: the multifaceted relationship. Journal of leukocyte biology. 2010;87(3):385-95.10.1189/jlb.070951720015961 Search in Google Scholar

12. GİRSCHİCK HJ, GUİLHERME L, INMAN RD, LATSCH K, RİHL M, SHERER Y., et al. Bacterial triggers and autoimmune rheumatic diseases. Clinical and experimental rheumatology. 2008;26(1 Suppl 48):S12-7. Search in Google Scholar

13. SEYAHİ E, POYRAZ BC, SUT N, AKDOGAN S, HAMURYUDAN V. The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatol Int. 2020;40(8):1229-38.10.1007/s00296-020-04626-0 Search in Google Scholar

14. European League Against Rheumatism (EULAR), Guidance for Patients during Covid-19 Outbreak, (2020) Updated March 17th Internet.https://www.eular.org/eular_guidance_for_patients_covid19_outbreak.cfm. April 25th, 2020 Search in Google Scholar

15. American College of Rheumatology (Acr), Guidance for Patients during Covid-19Outbreak, (2020) Updated April 14th. Search in Google Scholar

16. British Society for Rheumatology (Bsr), Guidance for Patients during Covid-19 Outbreak, (2020) Updated July 29th. Search in Google Scholar

17. VENERİTO V, LOPALCO G, IANNONE F. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatology international. 2020;40(5):827-8.10.1007/s00296-020-04566-9 Search in Google Scholar

18. COSKUN BN, YAGİZ B, PEHLİVAN Y, DALKİLİC E. Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Advances in rheumatology (London, England). 2021;61(1):55.10.1186/s42358-021-00211-6 Search in Google Scholar

19. FAVALLİ EG, MONTİ S, INGEGNOLİ F, BALDUZZİ S, CAPORALİ R, MONTECUCCO C. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis & Rheumatology. 2020;72(10):1600-6.10.1002/art.41388 Search in Google Scholar

20. ROSENBAUM JT, HAMİLTON H, CHOİ D, WEİSMAN MH, REVEİLLE JD, WİNTHROP KL. Biologics, spondylitis and COVID-19. Annals of the rheumatic diseases. 2020;79(12):1663-5.10.1136/annrheumdis-2020-217941 Search in Google Scholar

21. LÓPEZ-MEDİNA C, LADEHESA-PİNEDA L, GÓMEZ-GARCÍA I, PUCHELARRUBİA M, SEQUÍ-SABATER JM, ARMENTEROS-ORTİZ P., et al. Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. Joint Bone Spine. 2021;88(2):105085.10.1016/j.jbspin.2020.105085 Search in Google Scholar

22. KALYONCU U, PEHLİVAN Y, AKAR S, KAŞİFOĞLU T, KİMYON G, KARADAĞ Ö., et al. Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish journal of medical sciences. 2021;51(4):1615-23.10.3906/sag-2012-5 Search in Google Scholar

23. COSTANTİNO F, BAHİER L, TARANCÓN LC, LEBOİME A, VİDAL F, BESSALAH L., et al. COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence. Joint Bone Spine. 2021;88(1):105095.10.1016/j.jbspin.2020.105095 Search in Google Scholar

24. LANDEWÉ RB, MACHADO PM, KROON F, BİJLSMA HW, BURMESTER GR, CARMONA L., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the rheumatic diseases. 2020;79(7):851-8.10.1136/annrheumdis-2020-217877 Search in Google Scholar

25. MEHTA P, PORTER JC, CHAMBERS RC, ISENBERG DA, REDDY V. B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand? The Lancet Rheumatology. 2020;2(10):e589-e90.10.1016/S2665-9913(20)30270-8 Search in Google Scholar

26. EMMİ G, BETTİOL A, MATTİOLİ I, SİLVESTRİ E, Dİ SCALA G, URBAN ML., et al. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev, 2020. 19(7): p. 10257510.1016/j.autrev.2020.102575720013432376395 Search in Google Scholar

27. STRANGFELD A, SCHÄFER M, GİANFRANCESCO MA, LAWSON-TOVEY S, LİEW JW, LJUNG L., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-42.10.1136/annrheumdis-2020-219498784321133504483 Search in Google Scholar

28. TEPASSE PR, HAFEZİ W, LUTZ M, KÜHN J, WİLMS C, WİEWRODT R., et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. British journal of haematology. 2020;190(2):185-8.10.1111/bjh.16896730095032557623 Search in Google Scholar

29. ZHAO J, YUAN Q, WANG H, LİU W, LİAO X, SU Y., et al. Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(16):2027-34.10.1093/cid/ciaa344718433732221519 Search in Google Scholar

30. SCHETT G, MANGER B, SİMON D, CAPORALİ R. COVID-19 revisiting inflammatory pathways of arthritis. Nature Reviews Rheumatology. 2020:1-6.10.1038/s41584-020-0451-z730438132561873 Search in Google Scholar

31. CAMPBELL L, CHEN C, BHAGAT SS, PARKER RA, ÖSTÖR AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford, England). 2011;50(3):552-62.10.1093/rheumatology/keq34321078627 Search in Google Scholar

32. CARRARA G, BORTOLUZZİ A, SAKELLARİOU G, SİLVAGNİ E, ZANETTİ A, GOVONİ M., et al. Risk of hospitalisation for serious bacterial infections in patients with rheumatoid arthritis treated with biologics. Analysis from the RECord linkage On Rheumatic Disease study of the Italian Society for Rheumatology. Clinical and experimental rheumatology. 2019;37(1):60-6. Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo